# SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST

> **NCT06208748** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sarcoma Alliance for Research through Collaboration** · enrollment: 40 (estimated)

## Conditions studied

- Gastrointestinal Stromal Tumors
- GIST

## Interventions

- **DRUG:** Bezuclastinib in combination with sunitinib

## Key facts

- **NCT ID:** NCT06208748
- **Lead sponsor:** Sarcoma Alliance for Research through Collaboration
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-08-01
- **Primary completion:** 2026-06
- **Final completion:** 2027-06
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-10-31

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06208748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06208748, "SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06208748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*